Weekly Analysts’ Ratings Changes for IDEXX Laboratories (IDXX)

A number of firms have modified their ratings and price targets on shares of IDEXX Laboratories (NASDAQ: IDXX) recently:

  • 7/17/2025 – IDEXX Laboratories had its price target raised by analysts at Leerink Partners from $580.00 to $600.00. They now have an “outperform” rating on the stock.
  • 7/12/2025 – IDEXX Laboratories was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
  • 7/2/2025 – IDEXX Laboratories had its price target raised by analysts at Stifel Nicolaus from $510.00 to $540.00. They now have a “hold” rating on the stock.
  • 7/1/2025 – IDEXX Laboratories is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $625.00 price target on the stock.
  • 6/11/2025 – IDEXX Laboratories had its price target raised by analysts at Leerink Partners from $515.00 to $580.00. They now have an “outperform” rating on the stock.
  • 5/30/2025 – IDEXX Laboratories was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $520.87 on Tuesday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $549.52. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The firm has a market cap of $41.89 billion, a PE ratio of 48.14, a price-to-earnings-growth ratio of 3.74 and a beta of 1.54. The firm’s 50-day simple moving average is $523.58 and its 200-day simple moving average is $463.41.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. During the same quarter in the previous year, the company earned $2.71 EPS. The business’s revenue was up 3.6% on a year-over-year basis. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares of the company’s stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.98% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds have recently added to or reduced their stakes in IDXX. Mizuho Securities USA LLC lifted its position in IDEXX Laboratories by 45.4% during the fourth quarter. Mizuho Securities USA LLC now owns 7,761 shares of the company’s stock worth $3,209,000 after buying an additional 2,424 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at $15,876,000. Segall Bryant & Hamill LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $8,600,000. Florida Financial Advisors LLC boosted its position in shares of IDEXX Laboratories by 26.7% during the 4th quarter. Florida Financial Advisors LLC now owns 850 shares of the company’s stock valued at $351,000 after acquiring an additional 179 shares in the last quarter. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund bought a new position in IDEXX Laboratories in the 4th quarter valued at $455,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Receive News & Ratings for IDEXX Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc and related companies with MarketBeat.com's FREE daily email newsletter.